Concurrent RB1 loss and <i>BRCA</i> -deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinoma
Flurina A.M. Saner(University of Bern), Jennifer M. Koziak(Alberta Health Services), Jennifer Alsop(Manchester Academic Health Science Centre), Angela Brooks‐Wilson(BC Cancer Agency), Kazuaki Takahashi(Tokyo Shinagawa Hospital), Nicola S. Meagher(The University of Sydney), Timothy Budden(University of Manchester), Esther Elishaev(University of Pittsburgh), Penny Coulson(Institute of Cancer Research), Michael E. Carney(The University of Texas MD Anderson Cancer Center), Kara L. Cushing‐Haugen(Fred Hutch Cancer Center), Michael E. Jones(Institute of Cancer Research), Adelyn Bolithon(Cancer Institute of New South Wales), Brenda Y. Hernandez(Cancer Center of Hawaii), Gregg Nelson(Brigham and Women's Hospital), Marjorie J. Riggan(Duke Medical Center), Kathryn Alsop(Peter MacCallum Cancer Centre), C. Blake Gilks(Vancouver General Hospital), Elizabeth L. Christie(Peter MacCallum Cancer Centre), Matthias W. Beckmann(Universitätsklinikum Erlangen), Prafull Ghatage(University of Calgary), Simon A. Gayther(The University of Texas Health Science Center at Houston), Arndt Hartmann(Universitätsklinikum Erlangen), Therese Hoang(Peter MacCallum Cancer Centre), Catherine J. Kennedy(The University of Sydney), Aleksandra Gentry‐Maharaj(UCL Australia), Joy Hendley(Peter MacCallum Cancer Centre), Eunyoung Kang(University of Calgary), Scott H. Kaufmann(Mayo Clinic), Anna Jakubowska(Pomeranian Medical University), Sián Fereday(Peter MacCallum Cancer Centre), Jessica Boros(The University of Sydney), Holly R. Harris(Fred Hutch Cancer Center), Madeleine Courtney‐Brooks(University of Virginia Health System), Mona El‐Bahrawy(Al-Azhar University), Ahwan Pandey(Howard Hughes Medical Institute), Paul R. Harnett(The University of Sydney), Tibor A. Zwimpfer(University Hospital of Basel), Alison H. Brand(The University of Sydney), Kathleen I. Pishas(The University of Melbourne), Tomasz Kluz(University of Rzeszów), Alexander Hein, Cezary Cybulski(International Hereditary Cancer Center), Ramona Erber(Friedrich-Alexander-Universität Erlangen-Nürnberg), Dinuka Ariyaratne(Peter MacCallum Cancer Centre), Cheng‐Han Lee(National Tsing Hua University), Nadia Traficante(The University of Melbourne), Laura Twomey(Peter MacCallum Cancer Centre), Mercedes Jimenez‐Liñan(University of Kansas)
Cited by 5
Related Papers
Pan-cancer analysis of whole genomes
|Nature|2020|3.3k
<i>ARID1A</i> Mutations in Endometriosis-Associated Ovarian Carcinomas
|New England Journal of Medicine|2010|1.7k
Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency
|Nature Genetics|1999|1.7k
Whole–genome characterization of chemoresistant ovarian cancer
|Nature|2015|1.7k
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
|Clinical Cancer Research|2008|1.5k